Overview

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

Status:
NOT_YET_RECRUITING

Trial end date:
2028-07-14

Target enrollment:

Participant gender:

Summary

This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for participants with head and neck squamous cell cancer (HNSCC; a type of solid tumor that begins in outer tissue layer of the mouth \& throat).

Phase:

PHASE1

Details

Lead Sponsor:

Johnson & Johnson Enterprise Innovation Inc.

Treatments:

Cisplatin
Radiotherapy, Intensity-Modulated